Tricia Sterling has over 20 years of experience in the pharmaceutical and biotechnology space with 14 years working directly with patients and caregivers living with rare diseases.

Her career has focused on both Patient Advocacy as well as the development of Patient Support Programs for rare disease products pre-and post-commercialization.   She was responsible for designing the Patient Services Program, including access and distribution for Pegzilarginase as well as was instrumental in developing, supporting and mobilizing the ARG1- D patient community.

She brings a unique perspective as she has worked for several rare disease pharmaceutical companies and appreciates the role patients play in the drug development process and beyond.